Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Alicia C Shillington"'
Autor:
Alicia K Morgans, Simrun Grewal, Zsolt Hepp, Rupali Fuldeore, Shardul Odak, Cynthia Macahilig, Alicia C Shillington, Guru Sonpavde
Publikováno v:
Clinical Genitourinary Cancer. 20:543-552
The patterns of care and attrition of locally advanced or metastatic urothelial carcinoma (la/mUC) patients eligible for systemic therapy following PD-1/L1 inhibitors are unclear. The objective of this study was to evaluate the clinical characteristi
Autor:
Richard M. Trosch, Cynthia L. Comella, Stanley N. Caroff, William G. Ondo, Alicia C. Shillington, Brandon J. LaChappelle, Robert A. Hauser, Christof U. Correll, Joseph H. Friedman
Publikováno v:
CNS Spectrums. 28:219-219
ObjectivesCurrently utilized clinician-rated symptom scales for tardive dyskinesia (TD) have not kept up with the expanding spectrum of TD phenomenology. The objective of this study was to develop and test the reliability of a new instrument, the CTI
Autor:
Petros Grivas, Pedro C. Barata, Helen Moon, Thomas E. Hutson, Shilpa Gupta, Cora N. Sternberg, Vaidehi Dave, Chad Downey, Alicia C. Shillington, Geeta Devgan, Melissa Kirker, Sheena Thakkar, Howard M. Katzenstein, Abhijeet Bhanegaonkar, Frank Liu, Jason Brown, Guru P. Sonpavde
Publikováno v:
Journal of Clinical Oncology. 41:465-465
465 Background: The JAVELIN Bladder 100 clinical trial demonstrated a significant overall survival and progression-free survival benefit with avelumab 1LM + best supportive care (BSC) vs BSC alone for la/mUC not progressing on platinum-based chemothe
Autor:
Phyllis Foxworth, David J. Williamson, Richard C. Shelton, Martha Rhodes, Scott A. Langenecker, Jacqueline Pesa, Alicia C. Shillington, Margaret Holmes Rovner, Luis G. Allen
Publikováno v:
Journal of Affective Disorders. 275:299-306
Background: Shared decision-making (SDM) involves patients and clinicians choosing treatment jointly. SDM in mental health is hampered by lack of well-developed supporting tools. We describe an evidence-based patient decision aid (PDA) to facilitate
Autor:
Richard W. Joseph, Frank Xiaoqing Liu, Qing Harshaw, Todd L. Saretsky, Alan S. Pickard, Scott J. Diede, Cynthia Macahilig, Alicia C. Shillington, Vaidehi Dave
Publikováno v:
Quality of Life Research
Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in
Autor:
Petros Grivas, Pedro C. Barata, Helen Moon, Thomas E. Hutson, Shilpa Gupta, Cora N. Sternberg, A. Simon Pickard, Vaidehi Dave, Natalia Han, Alicia C. Shillington, Geeta Devgan, Ruth Kim, Sheena Thakkar, Howard Katzenstein, Abhijeet Bhanegaonkar, Frank Liu, Guru P. Sonpavde
Publikováno v:
Journal of Clinical Oncology. 40:TPS578-TPS578
TPS578 Background: The randomized phase 3 JAVELIN Bladder 100 trial demonstrated overall and progression-free survival (OS and PFS) benefit with Ave 1LM for la/mUC not progressed with platinum-containing chemotherapy (PCT). PATRIOT II aims to underst
Autor:
Todd A. Lee, Frank Xiaoqing Liu, Alicia C. Shillington, Emilie Scherrer, Vaidehi Dave, Scott J. Diede, Richard W. Joseph, Qing Harshaw, Cynthia Macahilig
Publikováno v:
Journal of medical economics. 23(2)
Background: Both pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are FDA-approved immunotherapy regimens for advanced melanoma (AM). Each regimen has different toxicity profiles pote...
Autor:
Martha M. Funnell, Qing Harshaw, Nananda F. Col, Robert A. Bailey, Jeffrey VanWingen, Alicia C. Shillington
Publikováno v:
Diabetes Therapy
Introduction Failure to intensify treatment for type 2 diabetes mellitus (T2DM) when indicated, or clinical inertia, is a major obstacle to achieving optimal glucose control. This study investigates the impact of a values-focused patient decision aid
Autor:
Alicia C. Shillington, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Richard W. Joseph, Cynthia Macahilig, Frank Xiaoqing Liu
Publikováno v:
Immunotherapy. 10(16)
Aim: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. Materials & methods: Total of 12 academic and satellite clinics contributed to this study. Descriptive and logisti
Autor:
Guru Sonpavde, Rupali Fuldeore, Simrun Kaur Grewal, Zsolt Hepp, Alicia K. Morgans, Cynthia Macahilig, Alicia C. Shillington, Shardul Odak
Publikováno v:
Journal of Clinical Oncology. 39:414-414
414 Background: There are a lack of published real-world data on treatment patterns for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) previously treated with programmed death 1/ligand 1 inhibitor (PD-1/L1i) therapy. The o